Human MDS-derived cell lines MOLM-13, SKM-1, F-36P, and AML cell lines U937 and MV-4-11 were used in this study. For all of the experiments, the cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum and penicillin-streptomycin. All of the experiments utilized logarithmically grown cells (3–4 × 105 cells/mL). MycoAlert (Lonza, Allendale, NJ, USA) assays were performed, demonstrating that all of the cell lines were free of mycoplasma contamination. Inducible MOLM-13 BCL-2 knock-down cells were obtained as previously described [9 (link)].
We obtained 5-Aza-T-dCyd and T-dCyd from the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (Rockville, MD, USA), and the Frederick National Laboratory, Frederick, MD, USA. ABT-199 was purchased from ChemieTek (Indianapolis, IN, USA). N-acetyl-L-cysteine (NAC) was purchased from Sigma-Aldrich (St. Louis, MO, USA). All of the drugs were dissolved in DMSO and reconstituted to 10 mM. The final DMSO concentrations did not exceed 0.1%. Aliquots of the drug were stored at −80 °C until use.
We obtained 5-Aza-T-dCyd and T-dCyd from the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (Rockville, MD, USA), and the Frederick National Laboratory, Frederick, MD, USA. ABT-199 was purchased from ChemieTek (Indianapolis, IN, USA). N-acetyl-L-cysteine (NAC) was purchased from Sigma-Aldrich (St. Louis, MO, USA). All of the drugs were dissolved in DMSO and reconstituted to 10 mM. The final DMSO concentrations did not exceed 0.1%. Aliquots of the drug were stored at −80 °C until use.
Free full text: Click here
